Abaxis completes acquisition of QCR & Trio Diagnostics Abaxis, Inc sildenafilonline.biz . , a medical products company manufacturing point-of-treatment instruments and consumables for the medical, research, and veterinary markets world-wide and providing reference laboratory services to the veterinary and research markets in the United States, announced today the completion of a stock purchase agreement to obtain 100 percent of QCR & Trio Diagnostics Limited, a United Kingdom based distribution organization. The transaction closed on November 17, 2014. Achim Henkel, Handling Director of Abaxis Europe GmbH, commented, After an extended and successful cooperation with QCR & Trio Diagnostics as our distribution partner in britain and Ireland, we now take direct market responsibility by closing on this acquisition.
And building a sustainable, fully integrated pharmaceutical company. This transaction does not effect Abbott’s previously released ongoing earnings-per-share guidance in 2010 2010.. Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl , which is currently in late Phase 2 trials for the treatment of chronic kidney disease .S., excluding certain Asian marketplaces. Related StoriesAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusKidney failing predictors in adolescents: an interview with Dr.D., senior vice president, pharmaceuticals, research and development, Abbott.